Triptan (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Triptan" in French language version.

refsWebsite

Global rank French rank

4wiley.com

222^nd place

129^th place

3sagepub.com

731^st place

771^st place

2adisonline.com

low place

2karger.com

4,489^th place

1,746^th place

1pharmasuisse.org

low place

1nejm.org

2,374^th place

298^th place

1neurology.org

9,919^th place

3,656^th place

1annals.org

low place

1,894^th place

adisonline.com

(en) Tfelt-Hansen P, De Vries P, Saxena PR, Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy, Drugs, 2000;60:1259-1287
(en) Nappi G, Sandrini G, Sances G, Tolerability of the triptans: clinical implications, Drug Saf, 2003;26:93-107

annals.org

(en) Snow V, Weiss K, Wall EM, Mottur-Pilson C, Pharmacologic management of acute attacks of migraine and prevention of migraine headache, Ann Intern Med, 2002;137:840-849

karger.com

content.karger.com

(en) Diener HC, Jansen JP, Reches A et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison, Eur Neurol, 2002;47:99-107
(en) Geraud G, Compagnon A, Rossi A, Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study, Eur Neurol, 2002;47:88-98

nejm.org

content.nejm.org

(en) Loder E, Triptan therapy in migraine, N Eng J Med, 2010;363:63-70

neurology.org

(en) Silberstein SD, Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 2000;55:754-762

pharmasuisse.org

Diagnostic et traitement de la migraine - Diagnostic et traitement de la migraine

sagepub.com

cep.sagepub.com

(en) Welch KM, Mathew NT, Stone P et al. Tolerability of sumatriptan: clinical trials and post-marketing experience, Cephalalgia, 2000;20:687-695
(en) Ferrari MD, Goadsby PJ, Roon KI, Lipton RB, Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials, Cephalalgia, 2002;22:633-658

journals.sagepub.com

Dahlöf CG, Infrequent or non-response to oral sumatriptan does not predict response to other triptans —review of four trials, Cephalalgia, 2006;26:98-106

wiley.com

www3.interscience.wiley.com

(en) Bartsch T, Knight YE, Goadsby PJ, Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception, Ann Neurol, 2004;56:371-381
(en) Dodick D, Lipton RB, Martin V et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine, Headache, 2004;44:414-425
(en) Evers S, Afra J, Frese A et al. EFNS guideline on the drug treatment of migraine -- revised report of an EFNS task force, Eur J Neurol, 2009;16:968-981

headachejournal.onlinelibrary.wiley.com

Diener HC, The risks or lack thereof of migraine treatments in vascular disease, Headache, 2020;60:649-653